![]() ![]() at the Athens State University Center for Lifelong Learning. On Sunday, Santa makes another trip to downtown Athens and will greet shoppers from 2:00 p.m. To conclude the day, the Limestone County Courthouse will show a special Christmas Light Show at 8 p.m. you can here the Jimmy Henderson Trio on the Marion Street steps of the Limestone County Courthouse. Following Santa’s visit, there will be a Tacky Holiday Sweater Contest on the Courthouse Steps at 3:00 p.m. Santa Claus and take photos at the Athens State University Center for Lifelong Learning from 2:00 p.m. on the Marion Street side courthouse steps while you skate on the rink. 17-19th.įriday’s entertainment includes Tom McClung from 6:00 p.m. Santa's Wrapping Station Complimentary Gift wrapping for purchases from Christmas Open House participants (listed below) at the Athens State University Center For Lifelong Learning, Nov. Blizzard Bash will include snow at the top of every hour and Christmas tunes coming from the downtown speaker system. In addition to the rink, the ServPro of Lawrence and Limestone Co. The rink will be located on Marion Street on The Square. The skating hours are as follows: Friday 4 p.m. the Tri-Green Equipment Ice Skating on the Square Rink. Subjects who have an active, known or suspected autoimmune disease. Requires treatment with strong CYP3A inhibitors known bleeding disorders or Major surgery within 4 weeks of first dose of study drug ![]() History of stroke or intracranial hemorrhage within 6 months prior to enrollment Concomitant use of warfarin or other Vitamin K antagonists Cetuximab or panitumumab (CRC cohort 4) Any taxane ( UC cohort of ibrutinib + paclitaxel) (cohort 2) Everolimus or temsirolimus (RCC cohort 1) Estimated Creatinine Clearance ≥30 mL/min (Cockcroft-Gault) docetaxel is administered, these subjects must have bilirubin within normal ![]() origin, such as hemolysis) with the exception of subjects in the GC cohort where Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of Alkaline phosphatase <3.0 x ULN or ≤5.0 x ULN if liver or bone metastases present limit of normal (ULN) if liver metastases, or ≤3 x ULN without liver metastases Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) ≤5.0 x upper Adequate hepatic and renal function defined as: Hemoglobin ≥9.0 g/dL for cohort 4 (CRC) for cohort 1 (RCC),all UC cohorts, and cohort 3 (GC) Platelet counts >100,000 cells/mm3 (100 x 109/L) for all UC cohorts Absolute neutrophil count ≥1500 cells/mm3 (1.5 x 109/L) For CRC: minimum of 2 and maximum of 4 prior regimens, which must have included bothĪn irinotecan and an oxaliplatin based regimen unless unable to tolerate irinotecan Which must have included a fluoropyrimidine regimen For gastric or GEJ adenocarcinoma: minimum of 1 and maximum of 3 prior regimens one of Of neo- or adjuvant therapy with a platinum chemotherapy. Locally advanced or mUC who have progressed on platinum chemo or within 12 months Score (CPS) of ≥ 10 without prior treatment. Locally advanced or mUC who are not eligible for cisplatin chemo with a PDL-1 For UC cohort 5: Minimum of 1 and maximum of 2 prior regimens, one of which must have For UC cohort 2: minimum of 1 and maximum of 2 prior regimens, one of which must have For RCC: minimum of 1 and maximum of 4 prior regimens, one or more of which must have ![]() Gastro-esophageal junctional (GEJ) adenocarcinoma, or K-RAS or N-RAS wild-type EGFR RCC (clear cell), urothelial carcinoma (UC) (transitional cell), gastric or Phase 2: To assess the ORR of ibrutinib combination therapy in GC, CRC, UC cohort 6, and ibrutinib as a single agent in UC cohort 5 Phase 2: To assess progression-free survival (PFS) of ibrutinib in combination with everolimus in RCC, and ibrutinib in combination with paclitaxel for UC cohort 2. Phase 1b: To confirm the RP2D of single-agent ibrutinib in UC cohort 5 Phase 1b: To determine the recommended Phase 2 dose (RP2D) of ibrutinib in combination with everolimus in RCC, paclitaxel in UC cohort 2, docetaxel in GC, cetuximab in CRC, and pembrolizumab in UC cohort 6 The purpose of this study is to evaluate the safety, tolerability, and efficacy of singleĪgent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel,ĭocetaxel, pembrolizumab or cetuximab in selected advanced gastrointestinal and genitourinary
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |